



Supplementary figure 1. Treatment with Scl-Ab increases cancellous bone mass in mice with established MM regardless of tumor burden. (a) Stratification of mice with established MM based on serum levels of IgG2b 4 weeks after Scl-Ab administration. n=3-6/group. (b) Number of osteolytic lesions in mice with low and high IgG2b levels. n=3-6/group; * $p \leq 0.05$ vs mice bearing 5TGM1 cells and receiving IgG. (c) Cancellous bone volume over tissue volume (BV/TV) of the distal tibia in mice with low and high IgG2b levels. n=3-6/group; * $p \leq 0.05$ vs mice bearing 5TGM1 cells and receiving IgG. Box plots: middle line in box represents the median, whiskers the 95% confidence interval of the mean, and circles are outliers from the 95% confidence interval.